Calcitonin sublingual - Vitapharm
Alternative Names: Calcitonin biobetter - VitaPharmLatest Information Update: 06 Sep 2017
At a glance
- Originator Vitapharm Technology Development
- Class Antihypercalcaemics; Biobetters; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 06 Sep 2017 Discontinued - Preclinical for Osteoporosis in China (Sublingual)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in China (Sublingual, Tablet)